Clearwater, Florida 33756


Purpose:

To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population. To collect data on the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in bifurcated lesions.


Criteria:

Key Inclusion Criteria - Symptomatic coronary artery disease including subjects with chronic stable angina, silent ischemia, and acute coronary syndromes including non-ST elevation and ST-elevation myocardial infarction - Subject is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use, and the Declaration of Helsinki - Subject requires treatment of a single de novo bifurcated lesion amenable to treatment with Resolute Onyx using the provisional stenting technique Exclusion Criteria: - Unprotected left main disease - Subjects with planned PCI of three vessel disease - Planned two stent technique (main branch and side branch) of a bifurcation - Subjects with more than one bifurcation lesion


NCT ID:

NCT03584464


Primary Contact:

Alissa Anderson
Phone: (763) 514-4000
Email: rs.onyxpas@medtronic.com


Backup Contact:

N/A


Location Contact:

Clearwater, Florida 33756
United States

Douglas Spriggs, MD
Phone: 727-510-3966
Email: rschdjs@cccheart.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.